APHINITY Trial in HER2+ Breast Cancer

Описание к видео APHINITY Trial in HER2+ Breast Cancer

Hope S. Rugo, MD, discusses the phase III APHINITY trial, looking at the addition of pertuzumab to standard adjuvant trastuzumab and chemotherapy for operable HER2-positive breast cancer. The benefit for adding pertuzumab was modest in this setting, and the regimen may be reserved for node-positive disease.

Комментарии

Информация по комментариям в разработке